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The inverse correlation between levels of dietary calcium and colorectal cancer (CRC) incidence has been extensively
investigated. However, the impact of supplemental calcium on cancer therapy remains unknown. We used four models of
CRC, Caco-2 and HCT116 human cancer cell lines and ApcMin/+ and azoxymethane carcinogen-induced mouse models, to
investigate the impact of a Western-style diet low in calcium (0.05%) vs. a similar diet but supplemented with calcium (5%) on
therapeutic targeting of the epidermal growth factor receptor (EGFR). We found that calcium supplementation combined
with pharmacologic blockade of EGFR results in an additive effect on tumor growth inhibition in all models. Unexpectedly,
the combined use of dietary calcium supplementation and EGFR inhibitors also resulted in elevated toxicity suggesting that
careful consideration be given when combining dietary supplements with prescribed cancer therapies.
Introduction
Exposure to Western-style diets results in hyperproliferation in
pancreatic, prostate, mammary and colonic epithelial cells.1-3 Some
of the growth effects caused by a Western-style diet can be attri-
buted to calcium deficiency since repletion with calcium suppresses
epithelial hyperproliferation. Calcium stimulates expression of a
membrane bound calcium-sensing receptor (CaR), and expression
of this receptor appears to decrease with progression of human
colorectal cancer (CRC).4 Furthermore, extracellular calcium and
its receptor promote CDH1 (E-cadherin) expression and inhibition
of CTNNB (β-catenin) activation in CRC.5
A review of 401 case-control studies, epidemiological studies
and randomized controlled trials (RCTs) revealed just two
appropriately-designed studies that provided evidence for a
potential preventative effect of calcium.6 Doses of calcium supple-
mentation in the two studies were 2,000 and 1,200 mg/day
(the recommended daily allowance) for 3 and 4 years, respec-
tively.7,8 Both studies revealed a moderate effect for calcium in
preventing the development of colonic adenomas, but only the
study using 1,200 mg calcium/day reached statistical significance.
In another study, calcium supplementation of 1,200 mg/day in
patients previously diagnosed with colorectal adenomas had a
protective effect even up to five years after the end of the study.9
Several studies using mouse models for CRC have confirmed
a role for calcium in preventing epithelial growth. Calcium
supplementation reverses both hyperproliferation and hyperplasia
of the distal colon in mice maintained on a Western-style diet and
calcium combined with vitamin D prevents Western-diet induced
colonic tumors.3,10 In another study mice maintained on a diet
supplemented with 1.0% calcium had increased apoptosis but no
change in proliferation in the distal colon compared with a control
diet.11 Similarly, low levels of calcium supplementation (40%
increase above recommended dose) to rats treated with the colon
carcinogen azoxymethane (AOM) resulted in inhibition of colon
carcinogenesis.12
Crosstalk between epidermal growth factor receptor (EGFR)
and CaR has been reported suggesting a possible combinatorial
treatment against CRC. Deregulation of the EGFR pathway
occurs in up to 50% of epithelial cancers, an observation that lead
to the development of numerous pharmacological agents to block
EGFR activity.13 Intestinal tumors in mice carrying ApcMin or
colon tumors in mice treated with AOM, both involving the
WNT/CTNNB pathway, display increased EGFR activity, and
treatment of these mice with small molecule inhibitors targeting
EGFR results in a significant decrease in tumor incidence.14-19
EGFR-inhibition using the EGFR-selective agent AG1478
inhibits calcium-mediated proliferation of rat cancer and
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fibroblast cells, while depletion of calcium was shown to cause
increased EGFR signaling via increased CDC42 activity, which in
turn led to increased CDH1 degradation in MCF-7 breast cancer
cells.20-22 G-protein coupled receptors (GPCR) like CaR may
mediate the effects of calcium on EGFR since GPCRs are known
to transactivate EGFR via regulation of ligand proteolytic cleavage
and shedding.21 The intracellular calcium/calmodulin complex
can also directly bind the juxtamembrane region of EGFR releas-
ing the kinase domain from the membrane thereby facilitating
activation of the receptor.23
Based upon the similarities between calcium supplementation
and EGFR inhibition, we investigated whether combinatorial treat-
ments would have greater therapeutic efficacy than EGFR inhibitor
monotherapy. Four models of CRC were used to demonstrate that
calcium has the potential to enhance efficacy of EGFR-targeted
therapies, but that special attention should be given to potential
adverse toxicities associated with high calcium levels.
Results
Calcium supplementation enhances EGFR inhibitor efficacy.
Mice from two mouse models for CRC, ApcMin/+ and AOM, were
randomly assigned to either a Western-style diet with low calcium
(0.05%) or a calcium-supplemented diet (5%), each with or
without the EGFR-inhibitor AG1478 (Fig. 1). Following treat-
ment tumor number and size was assessed in the small intestine
and colon of ApcMin/+ mice and colon of AOM-treated mice;
AOM does not induce small intestinal tumors.
Contrary to previous reports using EGFR inhibitors in mice
fed standard mouse chows, AG1478 did not significantly
reduce tumor number in the ApcMin/+ model fed a Western-style
diet (Fig. 2A).17,18 However, supplementation with calcium in
addition to AG1478 significantly reduced colon tumor number
compared with AG1478 alone. Small intestinal tumor number
was not significantly reduced by any treatment. However, all
treatments (AG1478 alone, calcium alone and AG1478 +
calcium) significantly reduced tumor size in the small intestine
of ApcMin/+ model (Fig. 2B). Colon tumor size was not affected by
any treatment (data not shown).
Unlike the ApcMin/+ model, AG1478 alone significantly reduced
tumor number in the AOM model in the context of a Western-
style diet (Fig. 2C). Calcium supplementation with AG1478
treatment resulted in a further reduction, but the additive effect
was observed only in female mice. None of the treatments
impacted tumor size in the AOM model (data not shown).
Calcium alone did not reduce tumor number and no treatment
modified the distribution of tumors along the GI tract in either
model (data not shown).
Calcium enhances growth inhibition of human CRC cell lines
by AG1478. The impact of calcium on AG1478-mediated
reduction in cell growth was also measured in two human CRC
cell lines, Caco-2 and HCT116, to determine if calcium has a
generalized effect on EGFR inhibition. Calcium alone produced a
dose-dependent reduction in cell viability for both cell lines
(Fig. 3A). In order to distinguish additive from synergistic inter-
actions with calcium, the maximal AG1478 dose producing less
than a 20% reduction in cell viability was determined for each cell
line (Fig. 3B). The combined effects of AG1478 (4 mM for
Caco-2 and 8 mM for HCT116) and calcium had an additive
effect on cell viability in both cell lines when compared with
calcium or AG1478 alone (Fig. 3C and D; additive model
p , 0.0001). These results suggested that calcium and EGFR
inhibition may impact the same cellular activity, with calcium
potentially enhancing the inhibitory effects of EGFR blockade.
Calcium enhances AG1478 inhibition of EGFR signaling.
The level of EGFR activity, as determined by phosphorylated
EGFR (pEGFR) was quantified in samples from mouse liver
tissue and human CRC cell lines to determine if calcium supple-
mentation can directly impact EGFR signaling. EGFR signaling
was also analyzed by sex since sex-dependent effects were observed
in vivo (Fig. 4).
In vivo, calcium alone did not significantly reduce tumor
number in either ApcMin/+ or AOM mouse models, and this is
reflected in absence of an effect on pEGFR. AG1478 also failed to
have a detectable effect on pEGFR signaling in ApcMin/+ mice
(Fig. 4A). However, AG1478 and AG1478 + calcium did reduce
levels of pEGFR in AOM-treated mice (Fig. 4A), consistent with
the observed reduction in tumor number.
The impact of calcium on AG1478-mediated EGFR inhibition
was also examined in vitro. Increasing levels of calcium along with
AG1478 reduced EGFR downstream signaling in a dose-
dependent manner (Fig. 4B). This inhibition was most evident
in pAKT levels for Caco-2 and pERK levels for HCT116 cells.
Baseline pEGFR levels were too low for detection using protein
gel blot analysis, consequently cells were treated for two hours
with AG1478 and/or calcium followed by EGF induction of
EGFR. ELISA was performed revealing that AG1478 reduced
pEGFR and calcium supplementation alone may actually enhance
Figure 1. Experimental design. At weaning (ApcMin/+) or 1 week following
the last carcinogen treatment (AOM) mice were randomly assigned to a
control (0.05% calcium) or calcium (5% calcium) supplemented diet, with
or without small-molecule EGFR inhibitor AG1478. ApcMin/+ mice were
treated for nine weeks and body weight and food consumption was
measured at the beginning and end of treatment. AOM mice were
treated for four months and body weight and food were monitored
biweekly throughout the treatment period.
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pEGFR, especially in the Caco-2 cell line (Fig. 4C). In both cell
lines, AG1478 effectively reduced pEGFR regardless of calcium
dose. pEGFR levels in AG1478-treated cells were too low for
detection of an additive effect between calcium and AG1478.
Calcium supplementation increases susceptibility to toxicity.
Potential adverse effects of supplemental calcium in combination
with EGFR inhibitor therapy were evaluated using standard
clinical parameters. Weekly and biweekly body weight was mea-
sured for ApcMin/+ and AOM-treated mice, respectively (Fig. 5A).
Female ApcMin/+ mice receiving calcium supplementation experi-
enced weight loss during the later period of treatment; a similar
albeit not significant trend was observed in females with the
AOM model. Overall, considering both models and sexes,
calcium supplementation did not have a significant impact on
early death when compared with non-calcium supplemented
diets (11.1 vs. 12.5%). However, closer examination of the
group that benefited most from the combinatorial treatment,
the AOM females, revealed that significantly more mice died or
were euthanized before the specific experimental endpoint (24%
of calcium-treated vs. 14% of no calcium treatment, p = 0.013;
data not shown).
Standard clinical chemistry tests were performed to investigate
the declining health of calcium treated mice. Typically calcium is
tightly regulated in the body, maintaining homeostatic levels
in the serum. However, both AG1478 (p = 0.011) and calcium
(p = 0.014) were associated with increased serum calcium con-
centrations compared with control mice in both mouse models
(Fig. 5B). In addition, serum alanine aminotransferase (ALT)
levels, an indicator of potential liver toxicity, were elevated in
AOM-treated mice given supplemental calcium compared with
the control group (p = 0.0003; Fig. 5C). At the end of treatment,
blood glucose levels were measured. Levels for both models
and all treatment groups stayed within normal ranges, though
ApcMin/+ mice were at the high end of normal, while AOM mice
were at the lower end. This is consistent with the increased
susceptibility to diet-induced obesity generally observed in
C57BL/6J mice, the strain background used for the ApcMin/+
model, compared with A/J mice, the strain background used
for the AOM model. AG1478 is associated with glucose levels
in both models but in opposite directions, with decreasing glucose
in ApcMin/+ (p = 0.0012) and increasing glucose in AOM-treated
mice (p = 0.023). When data from both models is combined, a
Figure 2. Effect of calcium on AG1478-mediated tumor (A) number and (B) size in ApcMin/+ and (C) tumor number in AOM models. Values are expressed as
a percent of control treatment. Number of mice (A and C) and number of tumors (B) are displayed in bars of graph. Equal numbers of males and females
were used and data for both sexes are shown. (C) A significant difference in tumor number is observed in AG1478 compared with Calcium/AG1478
treated mice only in females, but data for both sexes is shown. *p , 0.001; **p , 0.0001. Error bars show SEM.
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trend toward an association between calcium intake and glucose
reduction is also observed (p = 0.062). These observations are
consistent with previously shown associations of both calcium and
EGFR with glucose transport.
Discussion
Nutritional supplements have been on the rise in recent years as
people become more health conscience. Reports in the lay press
tout their benefits and even suggest that some dietary supplements
may be beneficial in treating or preventing cancer. An estimated
50% of cancer patients take some form of dietary supplementa-
tion.24 However, the impact of dietary supplements on established
cancers and, perhaps more importantly, their potential interaction
with conventional therapies is not well known.
To date literature reporting the usefulness of dietary supple-
ments in complementing or replacing conventional treatments
for cancer has been inconsistent and incomplete. While many
molecular targets have been identified for these dietary supple-
ments, their efficacy in treating or preventing cancer is unclear, in
large part due to the difficulty faced when studying supplements
and diets in humans. Perhaps more importantly, their impact on
cancer therapies, and on general health at high doses, is not well
understood.
The current study was designed to investigate the impact of
supplemental calcium on molecule-targeted therapies for CRC.
Figure 3. MTT assays of Caco-2 and HCT116 cell viability treated with AG1478 and/or calcium. (A) Calcium chloride and (B) AG1478 decrease cell viability
compared with the control (no treatment) in a dose dependent manner. Supplementing a constant dose of AG1478 with increasing doses of calcium
chloride results in reduced cell viability in an additive manner in both (C) Caco-2 and (D) HCT116 cells. Numbers within the bars indicate percent
reduction when compared with control untreated cells. Error bars show SD.
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Calcium alone has been intensely studied and is known to have
many roles in cell physiology, as well as interactions with
pathways involved in cancer. It has been suggested that calcium
possesses antitumor effects, but the mechanism is unclear. Some
theories involving the role of calcium in colonic tumorigenesis
include increasing apoptosis or inhibition of proliferation in the
colon, and binding bile salts that result from diets high in fat and
have been associated with colonic carcinogenesis.25
In this study we observed an antitumor effect with calcium
treatment in human CRC cell lines. The stronger effect observed
in Caco-2 cells may reflect the higher levels of CaR reported in
more differentiated tumors, since Caco-2 cells were derived from a
less progressed tumor than HCT116.
In vivo mouse models for CRC did not reveal a similar effect
on tumor growth. However, in both in vivo and in vitro models
an additive effect is observed when combining EGFR-targeted
inhibitor AG1478 with calcium. This is especially interesting in
the ApcMin/+ model where mice are unresponsive to AG1478 or
calcium alone, but small intestinal tumor size and colonic tumor
number are reduced in the combinatorial treatment. In the AOM
model this additive effect is only observed in females.
It appears that calcium may be more effective in the distal
region of the intestinal tract since reduction in tumor number is
only observed in the colons of ApcMin/+ and AOM-treated mice on
AG1478 + calcium. However, calcium alone does appear to
reduce tumor size in the small intestine of ApcMin/+ mice.
Finally, a sex-dependent effect on both EGFR signaling and
tumor reduction was observed in the mouse models. Among the
pathways that crosstalk with calcium and its receptor CaR is
EGFR, a pathway commonly deregulated in CRC. Calcium has
been shown to influence EGFR signaling through G-protein
coupled receptors and PKC. Due to sex differences observed here,
it is also possible that an interaction between CaR, EGFR and
estrogen receptors (ER) is contributing to the variable sex results
with regards to AOM tumor reduction and EGFR signaling
revealed through protein gel blot analysis.
In addition to the benefits of calcium supplementation,
potential negative effects on overall health must be considered.
Treatment with a high dose of calcium appeared to cause hyper-
calcemia, indicated by increased serum calcium and decreased
body weight. Liver toxicity also appeared to be higher according
to ALT levels.
Figure 4. Effect on signaling after AG1478 and calcium treatment. (A) In vivo: mice maintained on a control or calcium supplemented diet, with or
without AG1478, were injected with phosphatase inhibitor prior to euthanasia. EGFR activation was measured in liver protein lysates from ApcMin/+ and
AOM mice, separately for each strain and sex. (B) In vitro: protein was extracted from human CRC cells lines after a 4 h treatment with or without 4 mM
(Caco-2) or 8 mM AG1478 (HCT116) with 3.5 mM (“+”) and 4.5 mM (“++”) calcium chloride. (C) pEGFR ELISA was performed using protein extracted from
cells lines after 2 h treatment with or without 4 mM (Caco-2) or 8 mM AG1478 (HCT116) with 3.5 mM (“+”) and 4.5 mM (“++”) calcium chloride followed by
20 min treatment with EGF.
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Figure 5. General health of mice. (A) Comparison of body weight change for ApcMin/+ and AOM mice maintained on a control (solid lines) or calcium
(dashed lines) supplemented diets, with or without AG1478. Blood collected at the end of treatment was used for measurement of (B) serum calcium and
(C) alanine aminotransferase (ALT) levels. The normal lower and upper levels are indicated for each test. Error bars show SEM.
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Materials and Methods
Mice and treatments. Equal numbers of male and female A/J
mice were obtained from The Jackson Laboratory and maintained
on standard mouse chow (LabDiet 5058). At 4 months of age
mice were injected weekly with AOM (10 mg/kg body weight)
for 6 weeks. One week after the last AOM injection mice were
randomly assigned to control (0.05% calcium) or calcium supple-
mented (5% calcium) Western-style diet (based on Research Diets
D12450B) with or without 144 mg/kg chow of EGFR-inhibitor
AG1478 (LC Labs) for 12 weeks. At the end of treatment mice
were euthanized by CO2 asphyxiation and colons were flushed
with phosphate buffered saline (PBS), splayed on bibulous paper,
and scored for tumor number, size and location.
C57BL/6J-ApcMin/+ males were mated to wild-type B6 females,
and progeny containing the ApcMin/+ allele were weaned at three
weeks of age and assigned to one of the same four diets used for
the AOM model. An equal number of males and females were
used in each group. After nine weeks of treatment mice were
euthanized by CO2 asphyxiation and the entire intestinal tract was
flushed with PBS and splayed on bibulous paper. The intestine
was divided into four sections: small intestine (duodenum,
jejunum and ileum) and large intestine (colon) and scored for
tumor number and size.
Prior to euthanasia mice were injected with 10 ml/g body
weight of 5 mM phosphatase inhibitor sodium orthovanadate
activated with 50 mM hydrogen peroxide 15 min prior to use.26
Five minutes after injection, livers were removed and snap frozen
in liquid nitrogen. For protein gel blot analysis, total protein was
extracted with lysis buffer containing 10 mM TRIS-HCl (pH 8),
100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 1%
NP-40, 10% glycerol, 0.1% SDS, 0.5% sodium deoxycholate,
1 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 1 mM
Na3VO4, and 1 mM NaF. A Bradford protein assay was used to
determine protein concentration (Bio-Rad).
Body weight was monitored biweekly for the AOM model and
weekly for the ApcMin/+ model. Food weight was recorded at the
beginning and end of treatment for ApcMin/+ mice and biweekly for
AOM mice to estimate consumption. At euthanasia blood glucose
was measured using a FreeStyle Glucose Meter (Abbott) and
serum was collected for measurement of alanine aminotransferase
(ALT) and calcium levels by the UNC Animal Clinical Chemistry
Core Facility.
All mice were housed in an AAALAC approved-facility and
provided chow and water ad libitum. All experiments were
approved by the Institutional Animal Care and Use Committee.
Cell lines and treatments. Human colorectal adenocarcinoma
cells Caco-2 and carcinoma cells HCT116 were obtained
from the American Type Culture Collection (ATCC). Cell
lines were maintained in RPMI-1640+L-glutamine medium
(Invitrogen) supplemented with 10% fetal bovine serum,
2.0 mM L-glutamine, penicillin (10,000 U/mL), and streptomy-
cin (10,000 U/mL). Cells were grown at 37°C in 5% CO2.
Cells were treated with a dose range of 0.424 mM (base
concentration in media) to 5.5 mM calcium chloride (Sigma-
Aldrich) dissolved in media immediately before use. For EGFR
inhibitor treatment, AG1478 (LC Labs) was dissolved in DMSO
and cells were treated with a dose range of 0–15 mM with a final
DMSO concentration of 0.1%.
Cell viability was measured by seeding cells on 48-well plates
(4.0  104 Caco-2 cells/well or 2.5  104 HCT116 cells/well) in
triplicates 24 h before treatment. Cells were treated daily and
viability data was obtained at t = 72 h after plating for Caco-2
cells, and t = 96 h after plating for HCT-116 cells.
Relative cell growth was assayed with an MTT Cell Growth
Determination Kit (Sigma-Aldrich) according to manufacturer’s
instructions, and measured with a DU800 UV/Vis spectropho-
tometer (Beckman-Coulter). Relative cell viability was determined
by normalizing to the control (0.1% DMSO treated) cells.
To collect protein lysates, cells were seeded at 5  105 cells/
60 mm plate and 24 h later treated as described above with
increasing doses of CaCl2 (0.424–5.5 mM) and with or without
4 mM (Caco-2) or 8 mM (HCT116) AG1478. Following 24 h of
treatment protein was extracted with buffer containing 20 mM
HEPES (pH 7.4), 150 mM NaCl, 10% Glycerol, 1% Triton
X-100, 1 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin,
1 mM Na3VO4, and 1 mM NaF. A Bradford protein assay was
used to determine protein concentration (Bio-Rad).
Protein gel blot analysis. Thirty micrograms of liver protein for
the in vivo models or 15 mg of human CRC cell lysate for the in
vitro model was loaded onto 4–15% gradient TRIS-HCl gels
(Bio-Rad). After transfer to PVDF membranes for one hour,
membranes were blocked for 1 h in 5% BSA/TBST (containing
0.1% Tween) for rabbit anti-pEGFR and pMAPK1/3 (p42/44)
(Cell Signaling) or 5% milk/TBST for sheep anti-EGFR
(Millipore) and mouse anti-ACTB (β-actin) (Sigma-Aldrich).
Membranes were incubated with primary antibody overnight at
4°C, anti-EGFR and pMAPK1/3 antibodies were diluted 1:2,000
in 1% BSA/TBST, EGFR diluted 1:5,000 and ACTB diluted
1:10,000 in 5% milk/TBST. After washing, membranes were
incubated in secondary antibodies for one hour at room tempera-
ture. Secondary antibodies (Jackson ImmunoResearch) were
diluted 1:20,000 in the same solution as the primary antibody.
SuperSignal West Dura Extended Duration ECL (Pierce) was
used for visualization of proteins. Three replicates were performed
per treatment and model (and sex for mouse models).
ELISA. Cells were plated onto 60 mm plates and treated with
AG1478 and/or calcium chloride as described above. Following
two hours of calcium treatment, 100 ng/ml EGF (R&D Systems)
was added. After a 20 min EGF treatment, protein was isolated as
described above. The STAR phospho-EGFR (Tyr1173) ELISA
Kit (Millipore) was used according to manufacturer’s instructions.
Two replicates of 50 mg each were used.
Statistical analysis. Tumor number and size was analyzed using
a non-parametric Mann-Whitney test (Prism 4.0, GraphPad
Software). Linear mixed models were performed to assess whether
calcium levels and inhibitor were associated with absorption levels.
Models were evaluated with cell lines treated as a random effect
(Caco-2 and HCT116) and calcium levels (0.424, 1.5, 2.5, 3.5,
4.5, 5.5 mM) analyzed as both a linear effect (1 df) and without
any constraints (5 df). Tests for an interaction effect between
calcium levels and inhibitor on absorbance levels were performed
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to assess whether the effects of calcium levels and inhibitor on
absorbance levels were independent (additive). Finally, stratified
analyses were performed by cell type to assess whether evidence
for any associations between calcium levels/inhibitor and
absorbance levels was present in either cell type.
Analysis of covariance (ANCOVA) models was performed to
test whether model (AOM, ApcMin/+), sex, calcium intake and
inhibitor were associated with glucose levels, serum calcium levels
and ALT. Tests of interactions were also performed.
A non-parametric Mann-Whitney test was performed on final
body weight for mice in each treatment group (calcium and
non-calcium), separated by sex. Only comparisons that were
significant after correcting for multiple tests within each
experiment are shown.
Conclusion
We conclude that the impact of dietary supplementation on
conventional cancer therapies should be given consideration in
future preclinical and clinical trials. We observed using both
human CRC cell lines and mouse models of CRC that calcium
appears to enhance EGFR inhibitor therapy. However, this comes
at an elevated incidence of toxicity indicating that combinations
of conventional therapies with dietary supplements should be
closely monitored.
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